BRG1和BRM蛋白在前列腺癌中的表达

目的 探讨SWI/SNF催化亚基BRG1/BRM蛋白在前列腺癌及癌旁组织中的表达以及与前列腺发生发展之间的关系.方法 采用半定量免疫组织化学法配对评价前列腺癌及癌旁组织中BRG1和BRM蛋白的表达水平,分析BRG1和BRM表达与临床病理参数之间的关系.结果 在同一病例中,癌组织BRG1平均免疫反应得分为(57.0±9.8)分,远比前列腺癌旁组织的(19.0±4.1)分高,P=0.000 17,而且这种表达的差异在高级别的肿瘤中更显著;BRM呈现异质性表达,癌组织的平均免疫反应得分为(112±17)分,低于癌旁组织的(151±19)分,P=0.0047;同一病例的癌旁组织和癌组织中BRG1和BRM表达相反;大肿瘤组中癌组织BRG1的平均免疫反应得分与相应癌旁组织的比值明显高于小肿瘤组(P=0.0112).结论 SWL/SNF复合物蛋白BRG1和BRM的异常表达与前列腺癌的发生发展有关,BRG1的表达增强可能促进前列腺癌的生长.

Expression of BRG1 and BRM proteins in prostatic cancer

Objective To study the effect of BRG1 and BRM, the catalytic subunits expressed by SWI/SNF, in benign and malignant prostatic tissues and to correlate the BRG1/BRM expression with the development and progression of prostatic cancer. Methods The expression levels of the BRG1 and BRM proteins in benign and malignant prostatic tissues were studied using semi-quantitative immunohistochemistry. The results correlated with various clinical and pathologic parameters. Results The average immuno-reactive score for BRG1 expression in prostatic cancer tissues was significantly higher than that in benign prostatic tissues (57 + / - 9. 8 and 19 + / - 4. 1, respectively, P = 0. 000 17). The difference was more obvious in the high-grade cancer. On the other hand, BRM expression exhibited a heterogeneous pattern. The average immuno-reactive score for BRM expression was lower in cancer tissues than in benign tissues (112 +/-17 and 151 +/-19, respectively, P = 0.0047). BRG1 and BRM demonstrated a reciprocal expression pattern in benign and malignant tissues. The average immuno-reactive score for BRG1 expression was higher in the cancer cases with a larger tumor volume than in the cases with a smaller tumor volume (P = 0. 0112). Conclusions The expression of BRG1 and BRM correlates with the development of prostatic cancer. Increased BRG1 expression may have certain implications in tumor progression.